RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:NASH market and competitionThere are many permutations of what they could do, especially given the lack of a global sales force. IF any of these programs cross the finish line, what I am hoping is that they keep all they can (N.Am, Europe maybe) and bring in cash and partnerships to manufacture and distribute in Asia, ME, other parts. Also, partner with others who have a toxin or drug they can perfect on the SORT1+ platform in smaller cancers or specialty cancers. All that peripheral stuff not worth pursuing on their own but a partner would relish the chance. Those smaller areas can bring in plenty and you can keep the massive markets to your self. So you gain all the cash you need to get projects over the line to revenue generation territory (then you never worry about cash and start a dividend!), build the quickest and most significant value for your shareholders, and then if someone large comes knocking they have to massively pay us to give the upside up. LIke a SeaGen approach. Build it big and fast for yourself first. They owe that to us.
quote=SPCEO1]Given they have announced they are hiring someone to negotiate partnerships, they either think they are already there or will soon be. The effectively have a phase III NASH protocol approved by the FDA already (only minor adjustments likely needed after consultations). So, maybe such deals are closer than we think. My best guess is the partnerships may be more on the cancer side initially, given the many possibilities and targets for that indication. But NASH certainly could be partnerred as well. Given the amount of money they raised in the OO, it makes me think a NASH partnership might be desired since it will cost a whole lot more than what they raised to get that to the finish line.
palinc2000 wrote: Agreed!
Partnering will be a strategic decision and there is no way at this time to know if they should partner Nash or Oncology or both or neither....Phase 1 results in Oncology is the bare minimum needed to know if it has any value and FDa and EMA approval of the Phase 3 Protocol is also a bare minimum....
Wino115 wrote: Oncology is not a given, it needs to be proved up before you can rely on it for revenues and then think about partnering for NASH. You'd also want to move the NASH project along further so you can get proper value for it. But your scenario may be what happens. It's just that corporate strategy would be to see what oncology is and to further NASH. As has been said here before, Novo Nordisk is in the same balliwick with their semaglutide. Given all the KOLs expect combo therapies to eventually be tested, I'm sure someone will come knocking or they'll knock on an anti-fibrotics door. But now is not the time to do any of that. You're cashed up for the beginning of both trials. Let the hard data start to flow and hopefully support a much larger market cap.
jeffm34 wrote: Do you know what would make investors aware of TH's NASH program. A big licensing agreement with a company like Gilead to develop Egrifta in NASH. If the company's prospects for NASH are as bright as some here think, there are companies lining up to partner with TH. Then the company can focus on the bigger opportunity in oncology.
SPCEO1 wrote: I am not sure very many investors are even aware that TH has a ready to proceed letter from the FDA for NASH. So, it is not that they are wrong, it is that they just are unaware. And that is the company's fault for not selling the news well enough (and then quickly stomping on the news with the OO). And the sales job needed to begin long, long before the offering. The news of the FDA's approval for the company to proceed with the phase III NASH trial should have been something investors were waiting with baited breath for it to be released. But, just as in September when the company actually had a stunningly good conference call to announce the good news that they were moving into general NASH, very few people heard it and the stock reacted with a big yawn. They failed to lay the proper groundwork for that decision and it was ignored. They finally got the FDA's backing and gave no time for that to sink in before doing the offering which was led by cancer investors, rather than NASH investors.
The company really does have something of interest in NASH and neither you or anyone else has yet to make a cogent case to lead me to think otherwise. In fact, the case just keeps getting better for Egrifta in NASH as Dr. Grinspoon keeps adding more and more science to the equation.
The whole NASH thing has been a failure in marketing the opportunity to investors and that failure is made all the worse because it occurred in a huge bull market where any crazy idea has been well recieved by retail investors and even some institutional ones too.
jeffm34 wrote: So are you saying that every single investor is wrong except for a handful of people posting on this board?
scarlet1967 wrote: Believe me I haven't missed that and it's real so is the reason why.
jeffm34 wrote: You are missing the only thing that matters. The current share price the market has ascribed to TH's NASH program. It's not an oversight by investors. It's a reality.
scarlet1967 wrote: am I missing something here?
[/quote]